| First Author | Croci S | Year | 2004 |
| Journal | Cancer Res | Volume | 64 |
| Issue | 22 | Pages | 8428-34 |
| PubMed ID | 15548714 | Mgi Jnum | J:93904 |
| Mgi Id | MGI:3510092 | Doi | 10.1158/0008-5472.CAN-04-2341 |
| Citation | Croci S, et al. (2004) Immunological prevention of a multigene cancer syndrome. Cancer Res 64(22):8428-34 |
| abstractText | Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell-derived cytokines, in particular gamma-interferon, and by anti-HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues. |
